Article

Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: A randomized trial

Teachers College, Columbia University, New York, New York, United States
Neurorehabilitation and neural repair (Impact Factor: 4.62). 06/2007; 21(2):107-15. DOI: 10.1177/1545968306293449
Source: PubMed

ABSTRACT Persons with Parkinson disease (PD) exhibit decreased muscular fitness including decreased muscle mass, muscle strength, bioenergetic capabilities and increased fatigability.
This purpose of this investigation was to evaluate the therapeutic effects of resistance training with and without creatine supplementation in patients with mild to moderate PD.
Twenty patients with idiopathic PD were randomized to receive creatine monohydrate supplementation plus resistance training (CRE) or placebo (lactose monohydrate) plus resistance training (PLA), using a double-blind procedure. Creatine and placebo supplementation consisted of 20 g/d for the first 5 days and 5 g/d thereafter. Both groups participated in progressive resistance training (24 sessions, 2 times per week, 1 set of 8-12 repetitions, 9 exercises). Participants performed 1-repetition maximum (1-RM) for chest press, leg extension, and biceps curl. Muscular endurance was evaluated for chest press and leg extension as the number of repetitions to failure using 60% of baseline 1-RM. Functional performance was evaluated as the time to perform 3 consecutive chair rises.
Statistical analyses (ANOVA) revealed significant Group x Time interactions for chest press strength and biceps curl strength, and post hoc testing revealed that the improvement was significantly greater for CRE. Chair rise performance significantly improved only for CRE (12%, P=.03). Both PLA and CRE significantly improved 1-RM for leg extension (PLA: 16%; CRE: 18%). Muscular endurance improved significantly for both groups.
These findings demonstrate that creatine supplementation can enhance the benefits of resistance training in patients with PD.

2 Followers
 · 
59 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson’s disease (PD) is characterized as a chronic and progressive neurodegenerative disorder that results in a variety of debilitating symptoms, including bradykinesia, resting tremor, rigidity, and postural instability. Research spanning several decades has emphasized basal ganglia dysfunction, predominantly resulting from dopaminergic cell loss, as the primarily cause of the aforementioned parkinsonian features. But, why those particular features manifest themselves remains an enigma. The goal of this paper is to develop a theoretical framework that parkinsonian motor features are behavioral consequence of a long-term adaptation to their inability (inflexibility or lack of capacity) to meet energetic demands, due to neural metabolic deficits arising from mitochondrial dysfunction associated with PD. Here, we discuss neurophysiological changes that are generally associated with PD, such as selective degeneration of dopaminergic neurons in the substantia nigra pars compacta, in conjunction with metabolic and mitochondrial dysfunction. We then characterize the cardinal motor symptoms of PD, bradykinesia, resting tremor, rigidity and gait disturbance, reviewing literature to demonstrate how these motor patterns are actually energy efficient from a metabolic perspective. We will also develop three testable hypotheses: (1) neural metabolic deficits precede the increased rate of neurodegeneration and onset of behavioral symptoms in PD, (2) motor behavior of persons with PD are more sensitive to changes in metabolic/bioenergetic state, and (3) improvement of metabolic function could lead to better motor performance in persons with PD. These hypotheses are designed to introduce a novel viewpoint that can elucidate the connections between metabolic, neural and motor function in PD.
    Frontiers in Systems Neuroscience 01/2014; 8. DOI:10.3389/fnsys.2014.00242
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A doença de Parkinson (DP) é a doença neurodegenerativa motora mais prevalente na população, com maior incidência nos idosos. Algumas características importantes desta doença, como o seu caráter progressivo, a presença de sintomas não motores que em grande parte não respondem aos fármacos antiparkinsonianos disponíveis atualmente, e a perda de eficácia e o aparecimento de efeitos colaterais sérios após o tratamento crônico com fármacos dopaminérgicos, representam verdadeiros desafios às comunidades clínica e acadêmica. Existe um grande esforço na busca de agentes neuroprotetores e modificadores da DP, ou que aliviem os efeitos colaterais do tratamento, principalmente as discinesias, associados ao uso crônico da L-DOPA. Nas últimas duas décadas, um número crescente de trabalhos clínicos e experimentais tem sugerido o potencial do exercício físico como um agente paliativo ou adjuvante na DP. Os resultados desta tese demonstram que a capacidade neuroprotetora do exercício físico é dependente do modelo experimental utilizado, sendo observada em camundongos hemiparkinsonianos após lesão unilateral com 6-OHDA intra-estriatal. A prevenção da disfunção mitocondrial e do estresse oxidativo são mecanismos potencialmente envolvidos nesta ação neuroprotetora do exercício. Por outro lado, o mesmo protocolo de corrida em esteira durante seis semanas não protegeu a degeneração da via nigro-estriatal induzida pelo tratamento intranasal com MPTP em camundongos. Além disso, foi possível caracterizar uma série de propriedades modificadoras do exercício nos modelos experimentais da DP utilizados no presente estudo. O exercício em esteira ergométrica durante seis semanas atenuou os prejuízos motores e cognitivos induzidos, respectivamente, pela administração intra-estriatal de 6-OHDA e intranasal de MPTP em camundongos. Enquanto o exercício voluntário durante 14 dias em rodas de correr reduziu a severidade das discinesias induzidas pela L-DOPA em camundongos hemiparkinsonianos. Estes benefícios foram acompanhados de importantes modificações na plasticidade dos núcleos da base dos animais exercitados. O exercício melhorou a função da via indireta dos núcleos da base nos animais tratados com MPTP, através do aumento do número e resposta de receptores do tipo D2 para dopamina e da diminuição do turnover dopaminérgico. O exercício também preveniu modificações na neurotransmissão glutamatérgica e sinalização intracelular no estriado, potencialmente envolvidas no desenvolvimento das discinesias induzidas pela L-DOPA. Em conjunto, os resultados do presente estudo indicam o potencial do exercício físico como um agente modificador da DP, sendo este capaz de aliviar os prejuízos motores e cognitivos em animais submetidos a modelos experimentais da DP, além de diminuir as discinesias induzidas pelo tratamento com L-DOPA, enquanto a neuroproteção ainda permanece controversa. Palavras-chave: Exercício; doença de Parkinson; 6-OHDA; MPTP; L-DOPA, comportamento; neuroproteção; discinesias.
    08/2011, Degree: PhD, Supervisor: Rui Prediger
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypokinesia and bradykinesia as movement deficits of Parkinson disease are thought to be mediated by both basal ganglia dysfunction and a loss of muscle mass and strength commensurate with aging and decreased levels of physical activity. For these reasons, we sought to utilize resistance training as a means to increase muscle force and minimize hypokinesia and bradykinesia in persons with Parkinson disease and examine the effects of exercise and medication on Body Structure and Function (muscle force production and muscle cross-sectional area), Activity (mobility), and Participation (Health Status) outcomes. Forty-two participants were enrolled in a 12-week randomized clinical trial that compared 2 active exercise interventions: a standard care control group (Active Control) and an experimental group that underwent Resistance Exercise via Negative Eccentric Work (RENEW). Participants in both groups improved in muscle force production and mobility as a result of exercise and medication (P < 0.02). There were no significant interaction or between-group differences and no significant changes in muscle cross-sectional area or health status were observed. Effect sizes for exercise and medication combined exceeded the effect sizes of either intervention in isolation. Taken together, these results point to the complementary effects of exercise and medication on the Body Structure and Function and Activity outcomes but little effect on Participation outcomes. Video Abstract available for more insights from the authors (see Supplemental Digital Content 1, http://links.lww.com/JNPT/A92).
    Journal of neurologic physical therapy: JNPT 03/2015; DOI:10.1097/NPT.0000000000000086 · 2.89 Impact Factor